HeyJaredTim Smith
- Indexed articles, last 90 days
- 6
- Latest publication
- Oct 1, 2026
- Audience
- Checking…
- Earliest in this view
- Sep 28, 2026
Latest articles
NB-UVB Plus Upadacitinib Yields Higher Vitiligo Repigmentation Rates | HCPLive (opens the original)
Read excerpt
Frequently Asked Questions:How does upadacitinib perform long term in non-segmental vitiligo?In Viti-Up-1, F-VASI 75 rose from 33.1% at week 48 to 55.1% at week 76 among patients continuing upadacitinib 15 mg daily, with similar gains in Viti-Up-2.Does NB-UVB phototherapy add benefit to upadacitinib?In an 84-patient substudy, adding twice-weekly NB-UVB for 28 weeks produced higher F-VASI 75 and T-VASI 50 rates than upadacitinib alone, though statistical comparisons were not reported.
BE HEARD EXT: Bimekizumab Shows Improved HS Effects with Earlier Use | HCPLive (opens the original)
Read excerpt
Frequently Asked Questions:Does disease duration affect bimekizumab response in HS?In post hoc BE HEARD EXT data, 47.4% of patients diagnosed less than 2.38 years before treatment achieved IHS4-100 at 3 years, versus 33.3% of those diagnosed 10.74 years or more earlier.Can bimekizumab reduce tunnels in hidradenitis suppurativa?At 1 year, 30.7% of patients receiving bimekizumab had no draining or nondraining tunnels, up from 14.5% at baseline, per a pooled post hoc analysis of BE HEARD I and II.
Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS | HCPLive (opens the original)
Read excerpt
Frequently Asked Questions:What is tulisokibart?Tulisokibart is an investigational humanized monoclonal antibody targeting TL1A, designed to address both inflammation and fibrosis. It is being studied in HS and several other immune-mediated inflammatory diseases.What did the MK-7240-012 trial show?At week 16, 72% of high-dose and 64% of medium-dose patients with moderate to severe HS achieved HiSCR50, versus 35% with placebo, with adverse event rates comparable to placebo.
Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma | HCPLive (opens the original)
Read excerpt
Frequently Asked Questions:What is BO-112?BO-112 is an investigational dsRNA nanoparticle given by intralesional injection. It activates innate and adaptive antitumor immunity and is not approved by any regulatory authority.What did the SPOTLIGHT-204 trial show?In 46 evaluable patients with resectable primary BCC, 61% achieved visual and pathological response at Week 24 after 3 weekly injections, with no serious adverse events reported.
APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitis | HCPLive (opens the original)
Read excerpt
Frequently Asked Questions:What is zumilokibart?Zumilokibart (APG777) is an investigational, half-life-extended monoclonal antibody targeting IL-13, being developed for moderate to severe atopic dermatitis. It is not approved by any regulatory authority.What did the APEX Part B trial show?In 346 adults with moderate to severe atopic dermatitis, all 3 zumilokibart dose regimens achieved significantly greater EASI-75 response than placebo at week 16, and the mid-dose regimen is moving into phase 3
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.